These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8315628)

  • 21. WHA passes resolution on cancer prevention and control.
    Burki TK
    Lancet Oncol; 2017 Jul; 18(7):858. PubMed ID: 28602774
    [No Abstract]   [Full Text] [Related]  

  • 22. Preventive health screenings and health consultations in primary care increase life expectancy without increasing costs.
    Rasmussen SR; Thomsen JL; Kilsmark J; Hvenegaard A; Engberg M; Lauritzen T; Søgaard J
    Scand J Public Health; 2007; 35(4):365-72. PubMed ID: 17786799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The cost of preventing coronary heart disease.
    Elkan W
    Health Policy; 1992 May; 21(1):77-86. PubMed ID: 10119196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular disease.
    Hoare J
    Health Serv Manage; 1992 Oct; 88(7):19, 21. PubMed ID: 10122090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The things to come of SHAPE: cost and effectiveness of cardiovascular prevention.
    Diamond GA; Kaul S
    Am J Cardiol; 2007 Apr; 99(7):1013-5. PubMed ID: 17398203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of environmental approaches to disease prevention.
    Chokshi DA; Farley TA
    N Engl J Med; 2012 Jul; 367(4):295-7. PubMed ID: 22830461
    [No Abstract]   [Full Text] [Related]  

  • 27. Costs for screening, intervention and hospital treatment generated by the Malmö Preventive Project: a large-scale community screening programme.
    Norinder A; Persson U; Nilsson P; Nilsson JA; Hedblad B; Berglund G
    J Intern Med; 2002 Jan; 251(1):44-52. PubMed ID: 11851864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Danish Cardiovascular Screening Trial (DANCAVAS): study protocol for a randomized controlled trial.
    Diederichsen AC; Rasmussen LM; Søgaard R; Lambrechtsen J; Steffensen FH; Frost L; Egstrup K; Urbonaviciene G; Busk M; Olsen MH; Mickley H; Hallas J; Lindholt JS
    Trials; 2015 Dec; 16():554. PubMed ID: 26637993
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America.
    Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L;
    Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention research and its actual application to health services.
    Holder HD
    J Behav Health Serv Res; 2001 May; 28(2):118-29. PubMed ID: 11338324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
    Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Priorities among recommended clinical preventive services.
    Coffield AB; Maciosek MV; McGinnis JM; Harris JR; Caldwell MB; Teutsch SM; Atkins D; Richland JH; Haddix A
    Am J Prev Med; 2001 Jul; 21(1):1-9. PubMed ID: 11418251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International economic analysis of primary prevention of cardiovascular disease with pravastatin in WOSCOPS. West of Scotland Coronary Prevention Study.
    Caro J; Klittich W; McGuire A; Ford I; Pettitt D; Norrie J; Shepherd J
    Eur Heart J; 1999 Feb; 20(4):263-8. PubMed ID: 10099920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cost benefit analysis and preventive screening].
    Vandenbroucke JP
    Ned Tijdschr Geneeskd; 1981 Feb; 125(7):276-8. PubMed ID: 6785657
    [No Abstract]   [Full Text] [Related]  

  • 35. The cost implication of primary prevention in the HOPE 3 trial.
    Lamy A; Lonn E; Tong W; Swaminathan B; Jung H; Gafni A; Bosch J; Yusuf S
    Eur Heart J Qual Care Clin Outcomes; 2019 Jul; 5(3):266-271. PubMed ID: 30657891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of 'functional food'.
    Guesry PR
    Forum Nutr; 2005; (57):73-83. PubMed ID: 15702590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Waiting for prevention in Australia.
    Antill Y
    Lancet Oncol; 2013 Nov; 14(12):1157-8. PubMed ID: 24176558
    [No Abstract]   [Full Text] [Related]  

  • 38. The economics of prevention.
    Russell LB
    Health Policy; 1984; 4(2):85-100. PubMed ID: 10310959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On reducing cardiovascular disease to a rarity: clinical strategies and their cost-effectiveness.
    Lewis B; Watts GF; Sullivan DR
    Heart Lung Circ; 2010 Apr; 19(4):225-7. PubMed ID: 20149730
    [No Abstract]   [Full Text] [Related]  

  • 40. How much preventive care can we afford?
    Terry K
    Med Econ; 1993 Aug; 70(16):124-30, 132, 135-6. PubMed ID: 10127783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.